The growth and progression of prostate cancer are dependent on androgens and androgen receptor (AR), which act by modulating gene expression. Utilizing a gene microarray approach, we have identified the a1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gene. A heterodimeric cytoplasmic protein composed of one a and one b subunit, sGC mediates the widespread cellular effects of nitric oxide (NO). We report here that, in prostate cancer cells, androgens stimulate the expression of sGCa1. A cloned human sGCa1 promoter is activated by androgen in an AR-dependent manner, suggesting that sGCa1 may be a direct AR target gene. Disruption of sGCa1 expression severely compromises the growth of both androgendependent and androgen-independent AR-positive prostate cancer cells. Overexpression of sGCa1 alone is sufficient for stimulating prostate cancer cell proliferation. Interestingly, the major growth effect of sGCa1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the sGC enzyme. These data strongly suggest that sGCa1 acts in prostate cancer via a novel pathway that does not depend on sGCb1. Tissue studies show that sGCa1 expression is significantly elevated in advanced prostate cancer. Thus, sGCa1 may be an important mediator of the procarcinogenic effects of androgens.
Introduction
Androgens exert their biological effects through the androgen receptor (AR) (Chang et al., 1988) , a member of the nuclear receptor superfamily (reviewed by Kastner et al., 1995; Mangelsdorf et al., 1995) . One important target tissue of androgens and AR is the prostate. Like the development of normal prostate, growth and progression of prostate cancer are also dependent on androgens and AR (reviewed by Cunha et al., 1987) . Although this has been known for many years, only recent work has clearly demonstrated the importance of AR in prostate cancer. This work has shown that mutation of the AR is sufficient for causing prostate cancer development and progression in transgenic mice (Han et al., 2005) and that overexpression of AR converts prostate cancer growth from hormonesensitive to hormone-refractory (Chen et al., 2004) . In prostate carcinogenesis, androgens and the AR are important in regulating the proliferation and survival of prostate cells (reviewed by Jenster, 1999) . Androgen ablation in rats by castration leads to decreased proliferation and increased apoptosis of prostate luminal epithelial cells, resulting in the regression of the prostate gland (reviewed by Isaacs, 1999) . When physiological levels of androgens are replaced in a castrated rat, prostate epithelial (PrEC) cell proliferation is increased and apoptosis is decreased, leading to reconstitution of a normal prostate (Arnold and Isaacs, 2002) . All the data accumulated thus far strongly suggest that androgens, through the activity of AR, regulate the rate of cellular proliferation while inhibiting the rate of cell death in the prostate (Isaacs, 1984 (Isaacs, , 1994 . Dysregulation of this balance between cell proliferation and cell death is undoubtedly critical to the development of prostate cancer.
Many androgen-regulated genes either stimulate or inhibit cellular growth, underlying the complex nature of androgen-modulated gene expression and its role in prostate cellular proliferation (reviewed by Trapman and Cleutjens, 1997; Meehan and Sadar, 2003) . Through gene expression profiling studies in prostate cancer cells, we have identified soluble guanylyl cyclase (sGC)a1 as a novel androgen-regulated gene. sGCa1, together with sGCb1, form sGC, the receptor for nitric oxide (NO), the simple diatomic gas that has an important role in signal transduction in both animals and plants (reviewed by Krumenacker et al., 2004) . NO binding to sGC activates this enzyme to catalyse the formation of cGMP (3 0 , 5 0 -cyclic guanosine monophosphate) from guanosine 5 0 -triphosphate. cGMP will then activate a variety of proteins, including ion channels, protein kinases and phosphodiesterases (reviewed by Papandreou et al., 1998) .
Our results here demonstrate that dihydrotestosterone (DHT) can induce the expression of sGCa1 mRNA and protein, stimulate cGMP synthesis and activate a newly cloned human sGCa1 promoter driving the expression of reporter gene. In addition, sGCa1 is involved in the growth of both androgen-dependent and androgenindependent prostate cancer cells. Importantly, this growth effect is independent of NO and cGMP, suggesting the existence of a novel sGCal signaling pathway. Finally, examination of prostate tissues at different stages of carcinogenesis showed that the sGCa1 protein expression increases with increasing stage of prostate cancer.
Results
Gene array study identified sGCa1 as a novel androgenregulated gene Working from the hypothesis that novel androgen-regulated genes involved in androgen-induced proliferation of the prostate cancer cells LNCaP could be identified using gene microarrays, we developed an experimental strategy that utilized PC-3 cells stably transfected with AR (called A103 cells) as a negative control, as these cells exhibit DHT-repressed proliferation (see Figure 2b ; Yuan et al., 1993; Garcia-Arenas et al., 1995; Heisler et al., 1997) . Therefore, a gene array analysis was carried out with C14 (LNCaP cells transfected with empty pCI-Neo vector) and A103 cells using the Affymetrix human genome chip Hu95A, leading to the identification of several known (e.g. prostate-specific antigen (PSA) and human kallikrein 2 (hKLK2)) and several unknown androgen-regulated genes (S-Y Chen and L Shemshedini, unpublished results). Among the novel genes, sGCa1 was determined to be the most significantly DHT-induced gene using the Affymetrix algorithm.
DHT regulates the expression of sGCa1 mRNA and protein To confirm the gene array results, we analysed gene expression by semi-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) analysis of RNA from C14, A103 and primary PrEC cells. As shown in Figure 1a , sGCa1 mRNA was only expressed in LNCaP cells. This expression was induced by DHT similarly to PSA, a hallmark androgen-induced gene. Interestingly, sGCb1 mRNA was only weakly expressed in all three cell types and exhibited no DHT regulation. The two other isoforms of sGC, a2 and b2, were not detectably expressed in LNCaP cells (nor PC-3 cells) (C Cai and L Shemshedini, unpublished results). These results demonstrate that a1 and b1 are the major sGC subunits expressed in LNCaP cells, in agreement with an earlier study (Chen et al., 2002) .
As expected, Western blotting revealed a significant DHT induction of sGCa1 protein in LNCaP cells, but no detectable expression in PC-3 cells (Figure 1b) . The same observation was made at the cellular level by immunocytochemistry (Supplementary Figure 1) . On the other hand, no sGCb1 protein expression was detected in C14 cells (Figure 1c) . These results confirm the RT-PCR data and demonstrate that DHT enhances sGCa1 protein expression and that sGCb1 protein is not detectably expressed in LNCaP cells.
As DHT caused enhanced expression of sGCa1 protein, we expected elevated sGC activity in DHTtreated LNCaP cells. This hypothesis was tested directly by measuring cGMP levels using a cGMP enzymelinked immunosorbent assay (ELISA) in LNCaP cells treated with DHT. As shown in Figure 1d , DHT increased cGMP levels by more than twofold in LNCaP cells, but had no effect in A103 cells. These results show that DHT treatment can enhance sGC activity in LNCaP cells.
To examine the role of AR in sGCa1 expression, we used RNA interference to reduce expression of endogenous AR in LNCaP cells. As shown in Figure 1e , transfection of 21-nucleotide RNA (small interfering RNA (siRNA)) duplexes targeted to AR resulted in the elimination of endogenous AR, whereas a control siRNA did not. Significantly, the level of sGCa1 protein was markedly reduced in AR siRNA-treated cells, compared to control siRNA-treated cells (Figure 1e ). These results show that reduced AR protein levels correlate with reduced sGCa1 protein expression and suggest that sGCa1 may be an AR target gene.
To study this possibility, we PCR amplified isolated the human sGCa1 promoter using LNCaP cellular genomic DNA. Two PCR fragments were generated, both starting from the sGCa1 exon 1 and extending to either 1 kilobase pairs (kb) or 0.6 kb upstream of this exon. There is a consensus TATA box sequence (5 0 -TATAAA-3 0 ) just upstream of exon 1 and a near consensus androgen-responsive element (ARE) (5 0 -GTACAAATCTCCT-3 0 ) at about 0.7 kb upstream of the exon. The two PCR products were subcloned to make the reporter plasmids sGCa1(À600)-Luc and sGCa1(À1000)-Luc (Figure 1f ). Transfection into Cos cells of those two plasmids and pGL3, the promoter-less parental plasmid, resulted in promoter activity only from the 1-kb fragment that was strongly induced by DHT (sixfold) in the presence of transfected AR; DHT had only a weak activity in the absence of AR (Figure 1f) . The 0.6-kb fragment yielded substantially lower activity that was not significantly affected by either DHT or transfected AR (Figure 1f ). LNCaP cells exhibited a similar result, except that the magnitude of the DHT effect on the 1-kb fragment was lower (Supplementary Figure 2) . Importantly, siRNA-mediated inhibition of AR expression in LNCaP cells nearly eliminated the androgen induction of sGCa promoter activity (Supplementary Figure 2) . These results show that the 1-kb genomic fragment has DHT-inducible and AR-dependent promoter activity and strongly suggest that sGCa1 is a direct target of AR transactivation.
Chromatin immunoprecipitation (ChIP) was used to demonstrate that AR is recruited to the sGCa1 promoter within 4 h of DHT treatment (Figure 1g ). This is faster than AR binding to the PSA promoter ( Figure 1g ). These results demonstrate that ligandactivated AR can bind to the sGCa1 promoter in LNCaP cells.
sGCa1 is involved in androgen-dependent cellular growth of prostate cancer cells To test the hypothesis that sGCa1 expression in DHTtreated LNCaP cells is involved in the androgen induction of cellular proliferation, we disrupted sGC activity by either chemical ablation of sGC enzymatic activity or siRNA-directed downregulation of sGCa1 expression. First, cell growth conditions were optimized to measure androgen-induced proliferation. LNCaP cells grown in 2% fetal bovine serum (FBS)-containing medium exhibited a dose-dependent increase in cell number with either increasing concentrations of DHT (from 0.1 to 100 nM) (C Cai and L Shemshedini, unpublished results), as observed previously (Horoszewicz et al., 1983; Lee et al., 1995) , or increasing incubation time from 0 to 6 days and 100 nM DHT ( Figure 2a ). All subsequent proliferation experiments used these medium conditions.
1H-(1,2,4) oxadiazolo(4,3-a)quinoxalin-1-one (ODQ) specifically inhibits sGC enzymatic activity (Schrammel et al., 1996) . LNCaP cells were grown in medium containing 50 mM ODQ with or without 100 nM DHT. ODQ significantly inhibited DHT-dependent proliferation of LNCaP cells, implicating sGC activity in DHT-induced growth ( Figure 2b ). As expected, ODQ had no effect on A103 cells (Figure 2b ).
To test directly the importance of sGCa1 in cellular proliferation, we reduced sGCa1 expression using siRNA. LNCaP cells treated with sGCa1-targeted siRNA oligonucleotides showed a dose-dependent decrease in sGCa1 mRNA ( Figure 2c ) and protein ( Figure 2d ; C Cai and L Shemshedini, unpublished results). The sGCa1 siRNA had no effect on sGCb1 mRNA expression ( Figure 2c ) and an unrelated control siRNA had no effect on sGCa1 protein expression (Figure 2d ), verifying the specificity of our siRNA approach. Significantly, siRNA-mediated reduction of sGCa1 expression resulted in a significant decrease in androgen-induced LNCaP proliferation, whereas control siRNA or transfection reagent alone had no effect ( Figure 2e ). Additionally, the sGCa1 siRNA had no effect on the growth of PC-3 cells (Figure 2f ), which are deficient in sGCa1 protein (see Figure 1b ; Chen et al., 2002) . These results demonstrate a direct correlation between endogenous sGCa1 protein levels and LNCaP cellular proliferation, strongly suggesting an essential role for sGCa1 protein.
sGCa1 is involved in the growth of androgen-independent prostate cancer cells To determine if sGCa1 expression is unique to androgen-dependent LNCaP cells, we studied androgenindependent LNCaP cells that were established through continuous passage in culture Igawa et al., 2002) and closely mimic hormone-refractory prostate cancer (Igawa et al., 2002) . C51 and C81 cells proliferate in an androgen-unresponsive manner, whereas C33 are the parental androgen-dependent cells (Igawa et al., 2002) . RT-PCR analysis indicated that these cell lines express AR and PSA (Figure 3a) , as reported previously (Igawa et al., 2002) , as well as the prostate cancer marker EZH2 (Varambally et al., 2002) (Figure 3a) . Importantly, the androgen-independent LNCaP cells also express sGCa1 mRNA to a comparable level that is found in androgen-dependent LNCaP cells (Figure 3a) . sGCal protein is also highly expressed in another series of androgen-independent LNCaP sublines, C4, C4-2 and C4-2B (S-Y Chen and S Balk, unpublished results) (Chen et al., 1998) . These findings suggest that sGCa1 may have a role in androgenindependent cells (addressed below). As expected, similar low levels of sGCb1 mRNA are found in both androgen-independent and androgen-dependent cells (Figure 3a) .
To study a possible androgen regulation of sGCa1 in androgen-independent LNCaP cells, C81 cells were grown in either the absence or presence of DHT. Interestingly, C81 cells express high levels of sGCa1 mRNA ( Figure 3b ) and protein ( Figure 3c ) that are not significantly affected by the presence of DHT. Notably, these mRNA and protein levels found in C81 cells without DHT are comparable to what androgendependent cells express in the presence of DHT ( Figures  3b and c) , showing that androgen-independent LNCaP cells can express high levels of sGCa1 via a mechanism that does not depend on DHT.
To explore a proliferative role for sGCa1 in androgen-independent cells, we again utilized siRNAmediated repression of sGCa1 mRNA ( Figure 3d ) and protein (Figure 3e ) levels. As shown in Figure 3f , the androgen-independent proliferation of C81 cells is dramatically reduced by sGCa1 siRNA treatment. Control siRNA or transfection reagent alone had little effect (Figure 3f ). These data illustrate an important role for sGCa1 in androgen-independent growth of LNCaP cells.
sGCa1 overexpression is sufficient for inducing LNCaP cellular proliferation To determine if sGCa1 is sufficient for mediating LNCaP cellular proliferation, both androgen-dependent and -independent LNCaP cells were infected with two titers of an sGCa1-expressing adenovirus (Sinnaeve Note that control siRNA or transfection reagent had no effect on LNCaP proliferation. ANOVA analysis was performed that showed sGCa1 siRNA treatment resulted in significantly lower proliferation at 6 days than none (Po0.0001), control siRNA (Po0.0001) and reagent (Po0.0007), and these differences are indicated by asterisks. (f) Transfection of sGCa1 siRNA had no effect on PC-3 cellular proliferation. Bar graphs represent averages of three independent experiments plus s.d. Figure 4a , the higher virus titer markedly enhanced cell proliferation of LNCaP cells without DHT, which express substantially increased sGCa1 protein levels (Figure 4d ). Interestingly, this growth slightly exceeded the androgen-induced growth observed in uninfected cells (Figure 4a ), demonstrating that overexpression of sGCal is sufficient for reproducing the DHT effect on LNCaP cell growth. The sGCa1-expressing virus also weakly enhanced the DHT-induced growth of LNCaP cells (Figure 4a) . Importantly, an empty adenovirus had no effect on LNCaP cell proliferation at 2 or 20 multiplicity of infection (MOI); 200 MOI of empty virus inhibited cell growth (Figure 4c) . In contrast to the androgen-dependent LNCaP cells, the response of C81 cells to sGCa1 overexpression was marginal, with a slightly stronger positive effect in the absence than the presence of DHT (Figure 4b ). This suggests that the endogenous sGCa1 levels in C81 cells are sufficient for optimal cell growth. In addition, the data here collectively suggest that the concentration of sGCa1 is directly correlated to the growth potential of LNCaP cells.
et al., 2001). As shown in
The major sGCa1 effect on cellular proliferation is independent of NO and cGMP NO signaling depends on NO-activating sGC, leading to the synthesis of cGMP, which then activates several intracellular targets, including PKG (reviewed by Papandreou et al., 1998) . The levels of NO and cGMP have been changed to study their potential roles in LNCaP cellular proliferation. To sequester NO, LNCaP cells were treated with increasing concentrations of C-PTIO (2-carboxyphenyl-4,4,5,5-tetramethylimidazolineoxyl-1-oxyl-3-oxide) (Schrammel et al., 1996) , which had a small negative effect on LNCaP cell growth (Figure 5a ) that was markedly weaker than the sGCa1 siRNA effect (see Figure 3f) . Similarly, treatment of LNCaP cells with the low concentrations of the NO donor sodium nitroprusside (SNP) (Chen et al., 2002) had no effect on LNCaP cellular proliferation (Figure 5b ), although these concentrations significantly increased endogenous cGMP levels (J Omwancha and L Shemshedini, unpublished results). A high concentration (100 mM) of SNP was inhibitory (Figure 5b ), as observed previously (Mimeault et al., 2005) . A cGMP assay was used to ensure that C-PTIO and SNP had the expected effects on cellular cGMP levels (Supplementary Figure 3) . These results show that NO cannot reproduce the proliferation effect of overexpressed sGCal in prostate cancer cells. To analyse the role of cGMP, 8-bromo-cGMP (8-Br-cGMP) was added to LNCaP cells, resulting in significantly elevated levels of cellular cGMP (Figure 5d ). Interestingly, 8-Br-cGMP had no significant effect on cell growth (Figure 5c ), suggesting that endogenous cGMP levels are sufficient for cell growth. Importantly, when 8-Br-cGMP was added to cells transfected with sGCa1 siRNA, there was only a partial recovery of the cell growth (Figure 5e ), despite the fact that the cellular concentration of cGMP was markedly increased (Figure 5f ). This finding strongly suggests that the major function of sGCa1 in LNCaP cellular proliferation is independent of cGMP.
sGCa1 expression is highly elevated in prostate cancer tissues Validation of sGCa1 involvement in prostate carcinogenesis depends on demonstrating its expression in human tumor tissues. We have used RT-PCR to measure sGCa1 expression in prostate tissues purchased from the Cooperative Human Tissue Network (CHTN), identified as normal, benign prostatic hyperplasia (BPH) or malignant prostate cancer (MPC). Remarkably, sGCa1 mRNA is only detected in the two MPC samples (Figure 6a ). The absence of measurable sGCa1 expression in normal tissue is in agreement with its absence in PrEC cells (see Figure 1a) . To better characterize these tissues, the expression of several other genes was measured. PSA expression was high in both MPC and several BPH tissues. Notably, the expression pattern of sGCa1 paralleled that of EZH2, a gene marker for prostate cancer (Varambally et al., 2002) . E-cadherin expression was significantly reduced in the BPH and MPC tissues as compared to normal, consistent with the literature (Koksal et al., 2002) . All these data confirm that our tissue samples represent different stages of prostate cancer and demonstrate that sGCa1 is highly expressed in MPC. As expected (Jenster, 1999) , all tissues examined express AR (Figure 6a ). Interestingly, sGCb1 expression is weak in all the tissues (Figure 6a ), paralleling what was observed in the prostate cancer cell lines (see Figure 1a) . We evaluated the in situ expression of sGCa1 protein in wider range of prostate tissues using prostate cancer tissue arrays (n ¼ 45 from Imgenex). sGCa1 is weakly expressed in normal prostate tissue, and the expression tends to increase with increasing stage of cancer (Figure 6b ). This increased expression is observed in both epithelial and stromal cells (Figure 6b ). When expression levels were quantified and pooled according to prostate cancer stage, there is a linear increase in sGCa1 expression from normal tissue to stages 3 and 4 prostate cancer (Figure 6c ) (analysis of variance (ANOVA) indicates statistical difference in mean expression difference between normal and stages 3 and 4 is 0.495 and Po0.05). These data suggest that as prostate neoplasia progresses, there is a trend toward increased expression of sGCa1 protein.
Discussion
Several studies have shown that functional AR is expressed throughout the multiple stages of prostate cancer (reviewed by Jenster, 1999) and disruption of AR activity results in reduced proliferation of prostate cancer cells (Eder et al., 2002; Jiang et al., 2004; Chen et al., 2006) . Recently, it was also reported that AR overexpression was sufficient for converting the growth of prostate tumors from androgen-dependent to androgen-independent (Chen et al., 2004) . We describe in this paper the discovery of sGCa1 as a novel androgenregulated gene important in the proliferation of both androgen-dependent and androgen-independent prostate cancer cells. Most significantly, our data demonstrate a direct correlation between sGCa1 protein levels and cellular proliferation. Androgen-dependent cells exhibit DHT-induced cell proliferation and sGCa1 expression, whereas in androgen-independent cells DHT has no significant effect on either cell proliferation or sGCa1 expression. Indeed, the growth of androgenindependent LNCaP cells without DHT is comparable to the growth of androgen-dependent cells with DHT, and this coincides directly with similar sGCa1 expression levels. Thus, unlike PSA and other androgenregulated genes (Trapman and Cleutjens, 1997; Meehan and Sadar, 2003) , sGCa1 is an androgen-regulated gene that loses androgen regulation in hormone-refractory prostate cancer cells and therefore may be important in their androgen-independent growth. This contention is supported by our data demonstrating that downregulation of sGCa1 by siRNA blocks the growth of androgen-independent LNCaP cells. Microarray analysis was used to identify sGCa1 as an androgen-regulated gene, leading us to clone the human sGCa1 promoter and show it to be DHT inducible in an AR-dependent manner. Interestingly, previous work has found that the mouse sGCa1 promoter is estrogenregulated (Krumenacker et al., 2001) . Our promoter analysis suggests that sGCa1 may be an AR target gene, a possibility made more likely by the presence of a near consensus ARE approximately 0.7 kb upstream of exon 1. Furthermore, removal of this putative ARE by deletion of 0.4 kb from the 1-kb promoter fragment eliminated androgen activation of this promoter. Strong evidence for biological activity of this element was obtained from our ChIP assay, which showed AR binding to the sGCa1 promoter in LNCaP cells. All these strongly argue that sGCa1 is a direct AR target gene.
Our proliferation data with both androgen-dependent and -independent LNCaP cells demonstrate that sGCa1 is an important mediator of the growth-stimulatory effect of androgens and AR. Interestingly, our data further show that this sGCa1 effect in prostate cancer cells is independent of the known components of sGC signaling. First, we demonstrate that NO cannot reproduce the proliferative effect of overexpressed sGCa1 on prostate cancer cell growth and that cGMP only gives a small recovery on the growth of cells inhibited by transfected sGCa1 siRNA. Secondly, inhibition of PKGI and II activity does not affect cell growth (C Cai and L Shemshedini, unpublished results). Finally, LNCaP cellular proliferation is markedly increased by the overexpression of only sGCa1. Indeed, the endogenous levels in LNCaP cells of sGCa1 mRNA and protein (C Cai and L Shemshedini, unpublished results) are much higher than sGCb1. This large difference in mRNA expression was also observed in prostate cancer tissues. Gel filtration experiments indicate that most of the endogenous sGCa1 elutes from the column before sGCb1 (C-L Hsieh and L Shemshedini, unpublished results), strongly suggesting that sGa1 may be found in a complex different from the sGCa1/sGCb1 heterodimer. As both subunits are required for a catalytically active sGC enzyme, our data here strongly suggest that sGCa1 exerts its positive effect on prostate cancer cell proliferation independent of its enzymatic activity on cGMP synthesis and known mediators of NO signaling. Interestingly, our finding of dramatic expression differences between sGCa1 and sGCb1 in prostate cancer cells has also been seen in breast cancer, in which increased invasiveness correlates with an expression increase in sGCa1 and decrease in sGCb1 (Postovit et al., 2002) . Thus, sGCa1 may be an important mediator of not only androgen signaling in prostate cancer but also hormone-dependent cancers in general.
Materials and methods
Cell culture and siRNA transfection LNCaP cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% FBS. The medium for the C33 and C81 (Igawa et al., 2002) cells also contained 0.05 mg/ml gentamicin (Gibco, Carlsbad, CA, USA), and that for C14 cells had 0.1 mg/ml G418 (Gibco). PC-3 cells were grown in 10% FBScontaining F12K medium (Sigma), with 0.2 mg/ml G418 for A103 cells. PrEC cells were grown according to the manufacturer (Cambrex, Baltimore, MD, USA). Cos cells were grown in Dulbecco's modified Eagle's medium medium (Sigma) with 10% FBS.
siRNA (10 or 50 nM) was transfected into LNCaP, C81 or PC-3 cells using X-tremeGENE (Roche, Basel, Switzerland) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) (for AR siRNA experiment only) in 2% FBS-containing medium. After treatment with ethanol or 100 nM DHT, the cells were subjected to semiquantitative RT-PCR, Western blot or immunocytochemistry staining. siRNA oligo sequences are in Supplementary information. For sGCb1 expression in LNCaP cells, cells were transfected with sGCb1/CMV (Origene, Rockville, MD, USA) and treated with or without 100 nM DHT.
Adenovirus infection
LNCaP or C81 cells were infected with 2-200 MOI of either an adenovirus expressing the rat sGCa1 protein (kindly provided by Dr T Lincoln; Sinnaeve et al., 2001) or an empty adenovirus as a control. After 48 h, the cells were subjected to Western blotting. For the proliferation assay, the cells were treated with DHT 24 h after virus infection and then cell number quantified after 0-6 days.
Proliferation assay A total of 50 000 cells were grown in the 24-well plate with 2% charcoal-stripped FBS. After a 48-h incubation, either ethanol or 100 nM DHT was added into the wells. Also added were other chemicals, including ODQ (Sigma), C-PTIO (Sigma), SNP (Sigma) and 8-Br-cGMP (Sigma). The MTT assay (Sigma; Young et al., 1994) was performed after 0, 3 or 6 days of incubation following the manufacturer's protocol. Note that the cells with siRNA transfection were treated with DHT 24 h after transfection.
Plasmid and reporter assay
The promoter nucleotide sequence information of sGCa1 was obtained from the human genome database (National Institute Health) and analysed by using an online program (bimas. dcrt.gov/molbio/matrixs/). This revealed the presence of a consensus TATA box sequence (5 0 -TATAAA-3 0 ) and a near consensus ARE (5 0 -GTACAAATCTCCT-3 0 ) within 1 kb upstream of exon 1. LNCaP genomic DNA was used as a template to PCR-amplify the 1-kb sequence extending 40 bp into exon 1 of sGCa1. PCR oligo sequences are given in Supplementary Information. The 0.6-and 1-kb fragments were inserted into pGL3 vector (Promega, Madison, WI, USA). DNA sequencing confirmed that the sGCa1 5 0 flanking sequence had no mutations.
Cos cells were transiently transfected with 0.5 mg reporter plasmid, 2 mg pRL-tk-Luc to control for transfection efficiency (Shenk et al., 2001) , and 0.25 mg of AR using the FuGene 6 reagent (Roche) and incubated overnight. Cells were then treated with either ethanol or 100 nM DHT for 24 h, after which cell extracts were collected using the Mammalian Protein Extraction Reagent (Pierce) and subjected to a luciferase assay.
Semi-quantitative RT-PCR analysis RNA was isolated using the Trizol Reagent (Invitrogen) as recommended by the manufacturer. The RNA was subjected to RT using M-MLV Reverse Transcriptase (Fisher, HanovePark, IL, USA) following the manufacturer's protocol. The cDNA product was used for PCR using the PCR Master Mix (Promega). The PCR products were separated by agarose gel electrophoresis and stained with ethidium bromide. RT-PCR oligo sequences are in Supplementary information. Glycelaldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for RNA amount.
SDS-PAGE and Western blot
Cell extracts were prepared by boiling for 5 min in SDS Sample Buffer (63 mM Tris, pH 6.8; 20% glycerol; 2% SDS; 5% b-mercaptoethanol). Equal amounts of cell extracts were used in SDS-polyacrylamide gel electrophoresis and then electrophoretically transferred onto nitrocellulose blots. The nitrocellulose blots were incubated with a rabbit anti-sGCa1 or anti-sGCb1 antibody (Cayman Chemical, Ann Arbor, MI, USA) or a mouse anti-b-actin antibody (Abcam, Cambridge, MA, USA). Then, the blots were developed using the ECL chemiluminescence detection kit (Amersham, Buckinghamshire, England). b-Actin or b-tubulin was used as a control for protein amount.
Chromatin immunoprecipitation
LNCaP cells were grown to 70% confluence in RPM1640 containing 10% FBS. The medium was changed to RPMI1640 containing 2% dextran-coated charcoal FBS and cells were incubated for 2 days. Then, the cells were treated with either ethanol (À) or 100 nM DHT ( þ ) for 4, 8 or 24 h incubation, after which cells were collected and subjected to ChIP assay as described (Jia et al., 2003) . The anti-AR antibody PA1-110 (ABR) and Protein A-Sepharose (Amersham) were used to perform immunoprecipitation. PCR oligo sequences are in Supplementary information. cGMP ELISA assay LNCaP and A103 cells were grown to 60-70% confluency in the medium containing 10% FBS and then changed to 2% charcoal-stripped FBS medium. After 24 h of incubation, cells were treated with ethanol or 100 nM DHT, respectively, for 0-6 days. Cell extracts were prepared by boiling for 5 min in 0.05 M HCl (in PBS) and re-suspending in acetate buffer (Biomedical Technologies, Stoughton, MA, USA) and subjected to a cGMP ELISA assay with the cyclic GMP EIA Kit (Biomedical Technologies) following the manufacturer's protocol.
Tissue array assay
Prostate tissue array slide (Imgenex) was processed according to the manufacturer's protocol. The antibodies used were the anti-sGCa1 antibody (Cayman Chemical) and the Alexa Fluor 488 secondary antibody (Molecular Probes, Leiden, The Netherlands). 4 0 ,6-diamidino-2-phenylindole (DAPI) was used for nuclear staining. Note that the stage information for the 45 tissue samples was provided by Imgenex and this was standard clinical ABCD staging for prostate cancer.
Affymetrix gene chip assay C14 and A103 cells were grown to 60-70% confluency in 10% FBS and then changed to FBS-free medium. After 24 h of incubation, cells were treated with either ethanol or 100 nM DHT. After 48 h of incubation, total mRNA was isolated and subjected to gene chip analysis using chips purchased from Affymetrix (GeneChip Human Genome U95Av2 Array) according to the manufacturer's protocol.
